Author: Saraceni, Francesco; Scortechini, Ilaria; Mancini, Giorgia; Mariani, Marianna; Federici, Irene; Gaetani, Mariana; Barbatelli, Paolo; Minnucci, Maria Luisa; Bagnarelli, Patrizia; Olivieri, Attilio
Title: Severe COVIDâ€19 in a patient with chronic graftâ€versusâ€host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib Cord-id: pe8466n1 Document date: 2020_7_14
ID: pe8466n1
Snippet: Graftâ€versusâ€host disease (GVHD) is a common complication of hematopoietic stem cell transplant, which is known to be mediated by cytotoxic Tâ€cell effectors and dysregulated inflammatory cytokines. Similarly, the lung injury observed in severe COVIDâ€19 cases appears to be related to a massive production of proâ€inflammatory cytokines. The selective JAK1/2 inhibitor ruxolitinib has shown promising results in the context of GVHD, and different trials are currently underway in patients wit
Document: Graftâ€versusâ€host disease (GVHD) is a common complication of hematopoietic stem cell transplant, which is known to be mediated by cytotoxic Tâ€cell effectors and dysregulated inflammatory cytokines. Similarly, the lung injury observed in severe COVIDâ€19 cases appears to be related to a massive production of proâ€inflammatory cytokines. The selective JAK1/2 inhibitor ruxolitinib has shown promising results in the context of GVHD, and different trials are currently underway in patients with severe COVIDâ€19; nevertheless, no clinical observation of safety or efficacy of treatment with ruxolitinib in this context has been published yet. We describe a first case of severe COVIDâ€19 developed after hematopoietic stem cell transplantation in a patient with a concomitant chronic GVHD (cGVHD), in which a treatment with ruxolitinib was administered with good tolerance and positive outcome.
Search related documents:
Co phrase search for related documents- adaptive immunity and lung injury: 1, 2, 3, 4, 5, 6, 7
- adaptive immunity and lymphocyte count: 1, 2, 3, 4, 5
- adaptive immunity and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- adaptive immunity and macrophage activation syndrome: 1, 2, 3, 4, 5, 6
- adaptive immunity innate and lopinavir ritonavir: 1, 2
- adaptive immunity innate and lung injury: 1, 2, 3, 4, 5
- adaptive immunity innate and lymphocyte count: 1
- adaptive immunity innate and macrophage activation: 1, 2, 3, 4, 5, 6, 7
- adaptive immunity innate and macrophage activation syndrome: 1, 2, 3
- lopinavir ritonavir and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- lopinavir ritonavir and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- lopinavir ritonavir and macrophage activation: 1, 2, 3
- lopinavir ritonavir and macrophage activation syndrome: 1, 2, 3
- lopinavir ritonavir treatment and lung injury: 1, 2, 3
- lopinavir ritonavir treatment and lymphocyte count: 1, 2, 3, 4
- lung injury and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- lung injury and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- lung injury and macrophage activation syndrome: 1, 2, 3
- lymphocyte count and macrophage activation: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date